Xintela

Targinta develops first-in-class tumor-targeting antibodies and antibody-drug conjugates (ADCs) against the unique and patent protected target integrin α10β1. This cell adhesion receptor is highly expressed in some aggressive cancers such as glioblastoma but not at all in most normal tissues, making it an attractive target for ADCs.

TARG9 is a new generation ADC armed with a very potent cytotoxin. The concept builds on the fact that the tumor-targeting antibody delivers the cytotoxin very selectively to cancer cells, killing these but saving normal cells. The new data presented at the 2nd Integrin-Targeted Drug Development Summit in Boston includes the demonstration of strong and specific binding of TARG9 to integrin α10β1. Further, TARG9 was found to internalize at a high rate and to induce cell death of integrin α10β1-expressing glioblastoma cells, even at low picomolar concentrations. And importantly, a single dose of TARG9 effectively inhibited tumor growth for more than 2 months in a preclinical glioblastoma model.

“The observed effects on tumor growth are truly impressive and gives strong support for the continued development of TARG9", says Per Norlén, CEO of Targinta.

For further information please contact:
Per Norlén, CEO Targinta AB
Email: per.norlen@targinta.se
Phone: +46 46 275 65 00